Cost-Effectiveness of Nilotinib Versus Dasatinib for The Second-Line Treatment of Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Resistant or Intolerant To Imatinib, in Frame of Russian He ...
Abstract
Authors
N Goyert D Tran E Efremova C Apostopoulos D Grima